Splenic Enlargement During Neoadjuvant Chemotherapy for Gastric Cancer: Treatment-Related Phenomenon or Prognostic Biomarker?
Milzvergrößerung während neoadjuvanter Chemotherapie bei Magenkarzinom: behandlungsbedingtes Phänomen oder prognostischer Biomarker?
Journal of Clinical Medicine · 25.10.2026 · 15 (21) · 8303
DOI: 10.3390/jcm15218303 ↗Auf einen Blick
Bei 111 Patient:innen mit gastrischem Adenokarzinom nahm das Milzvolumen unter neoadjuvanter Chemotherapie meist zu. Die Zunahme war nicht mit radiologischer Response oder Gesamtüberleben assoziiert.
Fragestellung
Zusammenhang zwischen Veränderungen des Milzvolumens unter neoadjuvanter Chemotherapie bei Magenkrebs und radiologischer Response sowie Gesamtüberleben.
Methode
Retrospektive Kohortenstudie mit 111 Patient:innen mit gastrischem Adenokarzinom; Milzvolumen vor und nach NAC per CT gemessen; Response nach RECIST 1.1; Analyse mit logistischer und Cox-Regression.
Ergebnisse
Das mittlere Milzvolumen stieg von 250,59 ± 98,11 auf 335,40 ± 126,81 cm3 (p < 0,001). ΔSV% betrug 34,53 ± 15,72 %; bei 108 Patient:innen (97,3 %) nahm die Milz zu. Keine Assoziation mit Response oder OS.
Schlussfolgerung der Autor:innen
Das Milzvolumen nahm unter NAC bei Magenkarzinom deutlich zu. Die Ausprägung der Zunahme war jedoch nicht mit radiologischer Response oder OS verbunden und könnte ein behandlungsassoziiertes Phänomen sein.
Kernaussagen
- Milzvolumen stieg unter NAC bei 97,3 % der Patient:innen
- ΔSV% war zwischen Respondern und Nicht-Respondern ähnlich
- Keine Assoziation von ΔSV% mit radiologischer Response oder OS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.10.2026. Verfasst von Ezgi Altınsoy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology Department, Van Training and Research Hospital, Süphan Mahallesi Hava Yolu Kavşağı 1. Kilometre, Edremit 65300, Van, Türkiye. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Spleen volume (SV) may increase during systemic chemotherapy, potentially reflecting treatment-related hepatic, hematological, and immune alterations. However, the clinical significance of SV changes during neoadjuvant chemotherapy (NAC) for gastric cancer remains unclear. This study evaluated SV changes during NAC and their associations with radiological response and overall survival (OS).
Methods
This retrospective cohort study included 111 patients with gastric adenocarcinoma who received NAC followed by curative-intent gastrectomy. SV was measured on computed tomography before and after NAC using semiautomated volumetric segmentation. Relative SV change (ΔSV%) was calculated. Radiological response was assessed according to RECIST 1.1. Associations of ΔSV% with objective response and OS were evaluated using logistic and Cox regression analyses, respectively.
Results
Mean SV increased significantly from 250.59 ± 98.11 to 335.40 ± 126.81 cm3 (p < 0.001), with a mean ΔSV% of 34.53 ± 15.72%. SV increased in 108 patients (97.3%). Objective response was observed in 56 patients (50.5%). ΔSV% did not differ between responders and nonresponders (34.05 ± 15.66% vs. 35.03 ± 15.90%; p = 0.730) and was not associated with objective response after multivariable adjustment (OR per 10% increase, 0.932; 95% CI, 0.715–1.207; p = 0.578). ΔSV% was also not associated with OS (adjusted HR, 1.031; 95% CI, 0.859–1.236; p = 0.745).
Conclusions
SV increased markedly in nearly all patients during NAC for gastric cancer. However, the magnitude of this increase was not associated with radiological response or OS, suggesting that splenic enlargement during NAC may represent a treatment-associated phenomenon rather than a marker of antitumor efficacy or prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical Oncology Department, Van Training and Research Hospital, Süphan Mahallesi Hava Yolu Kavşağı 1. Kilometre, Edremit 65300, Van, Türkiye.
- Surgical Oncology Department, Antalya City Hospital, Göçerler Mahallesi 5379. Sokak, Kepez 07080, Antalya, Türkiye.
- Surgical Oncology Department, Ordu University Training and Research Hospital, Bucak Mahallesi Nefsi Bucak Caddesi, Altınordu 52200, Ordu, Türkiye.
- Radiology Department, Faculty of Medicine, Ankara University, Balkiraz Mahallesi Tıp Fakültesi Caddesi, Mamak 06620, Ankara, Türkiye.
- Surgical Oncology Department, Faculty of Medicine, Ankara University, Balkiraz Mahallesi Tıp Fakültesi Caddesi, Mamak 06620, Ankara, Türkiye.
ORCID-Profile: Ezgi Altınsoy, Veysel Cem Özcan, Abdurrahman Başpınar, Selim Tamam
Zitieren
APA
Altınsoy, E., Özcan, V. C., Başpınar, A., Gülpınar, B., Tamam, S., Çulcu, S., & Demirci, S. (2026). Splenic Enlargement During Neoadjuvant Chemotherapy for Gastric Cancer: Treatment-Related Phenomenon or Prognostic Biomarker?. Journal of Clinical Medicine, 15(21), 8303. https://doi.org/10.3390/jcm15218303
Vancouver
Altınsoy E, Özcan VC, Başpınar A, Gülpınar B, Tamam S, Çulcu S, et al. Splenic Enlargement During Neoadjuvant Chemotherapy for Gastric Cancer: Treatment-Related Phenomenon or Prognostic Biomarker?. Journal of Clinical Medicine. 2026;15(21):8303. doi:10.3390/jcm15218303
BibTeX
@article{Altnsoy2026,
author = {Altınsoy, Ezgi and Özcan, Veysel Cem and Başpınar, Abdurrahman and Gülpınar, Başak and Tamam, Selim and Çulcu, Serdar and Demirci, Salim},
title = {Splenic Enlargement During Neoadjuvant Chemotherapy for Gastric Cancer: Treatment-Related Phenomenon or Prognostic Biomarker?},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8303},
doi = {10.3390/jcm15218303}
}
EUVIMED